Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries
NCT ID: NCT01503567
Last Updated: 2017-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
282 participants
OBSERVATIONAL
2012-01-31
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Defeat Rare Disease in Asia and Pacific (APAC) DRDA - Haemophilia
NCT07163260
Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors
NCT01234545
Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World
NCT01217255
Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A
NCT02697370
Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies
NCT03405337
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
ECOLOGIC_OR_COMMUNITY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Subjects 6 to 18 years old without inhibitors
No treatment given
Subject will only fill out a questionaire
Subjects 6 to 18 years old with inhibitors
No treatment given
Subject will only fill out a questionaire
Subjects above18 years old without inhibitors
No treatment given
Subject will only fill out a questionaire
Subjects above 18 years old with inhibitors
No treatment given
Subject will only fill out a questionaire
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No treatment given
Subject will only fill out a questionaire
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male patients at least 6 years old with diagnosis of severe congenital haemophilia A or B with or without inhibitors
* Patients receiving on demand replacement factors/bypassing agents therapy
Exclusion Criteria
* Patients on currently active treatment for HCV (Hepatitis C Virus) or HIV (Human Immune Deficiency Virus) infections
6 Years
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Registry (GCR, 1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational Site
Bangalore, , India
Novo Nordisk Investigational Site
Casablanca, , Morocco
Novo Nordisk Investigational Site
Muscat, , Oman
Novo Nordisk Investigational Site
Sandton, , South Africa
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gupta N, Belhani M, Benbouzid A, Andaloussi M El, Maani K, Mahlangu J, Wali Y, Saad HA, Fegoun SB el. The Haemocare Protocol - A composite method to measure the disease burden from Haemophilia in developing countries. European Hematology Association 2013; Country: Sweden City: Stockholm
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Trials at Novo Nordisk
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1124-6665
Identifier Type: OTHER
Identifier Source: secondary_id
HAEM-3971
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.